Evolutionarily conserved Notch signaling has a crucial role in cell fate determination and various developmental processes, as it translates cell-cell interactions into specific transcriptional programs 1, 2 . Temporal and spatial modulation of this pathway can markedly affect proliferation, differentiation and apoptotic events 3 . Moreover, the timing of Notch signaling can lead to diverse effects within the same cell lineage 4, 5 . In mammals, activation of up to four Notch receptors by membrane-bound ligands initiates a process leading to presenilinmediated cleavage and release from the membrane of the Notch intracellular domain (NICD), which then traffics to the nucleus. The NICD subsequently regulates the expression of genes, in cooperation with the transcription factor RBP-Jk and Mastermind-like proteins.
The observation that mutations in the Notch ligand Delta-like-3 (Dll-3) and in the g-secretase presenilin-1 cause axial skeletal phenotypes initially caused researchers to link Notch signaling with axial skeletal development 6, 7 . Recently, several in vitro studies yielded conflicting results that implicated the Notch pathway in the regulation of osteoblast differentiation; however, the in vivo role of Notch signaling in bone homeostasis still remains unknown [8] [9] [10] [11] [12] .
In this study, we investigate the tissue, cellular and molecular consequences of both gain and loss of function of Notch signaling in committed osteoblasts.
RESULTS

Gain of Notch function results in severe osteosclerosis
To determine the pathological consequences of in vivo gain of Notch function during bone formation and homeostasis, we generated transgenic mice expressing the Notch1 intracellular domain (N1ICD) under the control of the type I collagen (Col1a1) promoter ( Supplementary Fig. 1a ,b online). Here, gain of Notch function would occur in committed osteoblastic cells, as Col1a1 is both an early and a late marker of the osteoblastic lineage. Notably, founder mice expressing high levels of the transgene were small at birth and showed progressive growth retardation. Analysis of three established lines at 4 weeks of age showed increased bone mass on radiographs and a thickened, osteosclerotic appearance after skeletal preparations ( Fig. 1a and Supplementary Fig. 1c ). As determined by histology, marrow spaces in 4-week-old transgenic mice were filled with trabecular bone composed predominantly of immature woven, rather than lamellar, bone and surrounded by fibrotic marrow containing cells with morphologic features of early osteoblastic precursors, suggesting the increased proliferation of these cells (Fig. 1b) . The cortices of the bones were also composed of woven bone, and this phenotype was present in 11-week-old mice as well. Toluidine blue staining of 11-week-old transgenic mice indicated an increased number of osteoblasts in vertebrae (Fig. 1c) . Quantitative histomorphometry of an established mouse line confirmed the significant increase in trabecular bone volume and osteoblast surface area, which would be consistent with the high bone mass being due to increased osteoblastic activity (Fig. 1d) . This increased osteoblastic activity led to increased production of osteoid (Fig. 1d ) and bone formation ( Supplementary Fig. 1d ).
Because bone formation and resorption are coupled in vivo, we analyzed the status of osteoclasts by staining for tartrate-resistant acid phosphatase (TRAP) activity in osteoclasts from bone sections of 4-week-old mice. Although total TRAP staining was qualitatively increased in the limb sections of transgenic mice ( Supplementary Fig. 1e ), consistent with increased bone mass and remodeling, the osteoclastic parameters normalized to bone surface (that is, osteoclast number per mm of bone surface and osteoclast surface) were significantly decreased in trabecular bone of transgenic mice (Supplementary Fig. 1e ). Together, these data support the notion that gain of Notch function in committed osteoblastic lineage cells stimulates the proliferation of early osteoblastic precursors that differentiate into immature osteoblasts producing increased amounts of immature woven bone. Although osteoclastic activity was secondarily stimulated by this massive osteoblastic proliferation, bone formation much greatly outweighed bone resorption, leading to an osteosclerotic phenotype.
To determine the underlying cellular and molecular mechanism for the increase in early osteoblastic precursors in transgenic bone, we cultured postnatal day 6 (P6) calvarial osteoblasts and found significantly increased numbers of BrdU-positive cells, consistent with increased cellular proliferation (Fig. 1e) . Quantitative real time RT-PCR (qRT-PCR) of 1-month-old calvarial total RNA showed an increased abundance of early osteoblastic differentiation markers, including osterix (encoded by Sp7), alkaline phosphatase and bone sialoprotein. In contrast, later markers of osteoblast differentiation, including osteocalcin, were downregulated (Fig. 1f) . To exclude the possibility that the increased bone mass was due to decreased osteoclastic activity, we assessed the expression of markers that regulate macrophage differentiation along the osteoclastic lineage in the forelimbs of 4-week-old transgenic mice. RANK ligand (RANKL, encoded by Tnfrsf11a), osteoprotegerin, TRAP and macrophage colony-stimulating factor (M-CSF) were all highly expressed, suggesting that the hyperproliferation of the early osteoblastic pool was associated with increased production of both pro-(RANKL and M-CSF) and anti-(osteoprotegerin) osteoclastic differentiation factors by osteoblasts (Fig. 1g) . Notch regulates osteoblastic transcription factors How Notch signaling regulates these processes on a biochemical level is unknown. Osteoblast differentiation from mesenchymal stem cells and subsequent maturation steps require the function of the runtdomain transcription factor Runx2 and the zinc-finger transcription factor osterix. Runx2 is required for commitment of mesenchymal osteochondroprogenitors to the osteoblastic lineage, differentiation into mature osteoblasts and terminal differentiation into osteocytes. In contrast, osterix is important in expansion of the early osteoblastic pool 13 . Whereas bone sialoprotein and alkaline phosphatase are markers of early osteoblasts, osteocalcin is a marker of later, mature osteoblasts. To determine the mechanistic basis of Notch action in this context, we tested the effects of Notch expression on these key transcriptional regulators of osteoblast differentiation and maturation. N1ICD alone was able to directly bind Runx2 and repress its transactivation of a reporter osteocalcin enhancer in vitro (in Cos7 and rat osteosarcoma Ros17/2.8 cells; Fig. 2a-c and Supplementary  Fig. 1f ). Electrophoretic mobility shift assays (EMSAs) showed that N1ICD could inhibit Runx2 binding to a target cis element in the type X collagen promoter ( Supplementary Fig. 1g ). Notably, there was marked downregulation of Runx2 protein in P2 calvaria of transgenic mice ( Fig. 2d) . Thus, the downregulation of osteocalcin and the delay in late osteoblast differentiation in vivo is probably due, in part, to direct repression of Runx2 by Notch at the protein level. At the same time, we observed upregulation of osterix mRNA expression in the P2 calvaria of transgenic mice (Fig. 1f) . Moreover, N1ICD activated the Sp7 promoter in transient transfection studies in C2C12 cells that were induced to differentiate into osteoblasts with bone morphogenic protein-2 treatment (Fig. 2e) . These data suggest that Notch can induce proliferation of committed osteoblast precursors by directly upregulating transcription of Sp7, while inhibiting their maturation by repressing the function of Runx2.
To further understand the biochemical basis of the effects of Notch on osteoblastic proliferation, we analyzed the expression of cell cycle markers and detected increased mRNA expression of cyclin D and cyclin A by qRT-PCR in osteoblasts overexpressing N1ICD (Fig. 2f ). This correlated with increased cyclin D and cyclin E expression at the protein level (Fig. 2g) . We did not, however, observe significant differences in the abundance of two other important cell cycle regulators implicated in bone homeostasis, p53 and Rb. Of note, it has been shown with in vitro and ex vivo studies that Runx2 can suppress osteoblast proliferation and promote osteoblast maturation by supporting exit from the cell cycle 14, 15 . Moreover, cyclin D1-cyclin-dependent kinase-4 (cdk4) can induce Runx2 ubiquitination and degradation, and thus Runx2 activity can be regulated by the cell cycle machinery 16 . Hence, gain of Notch function can inhibit osteoblast maturation by direct repression of Runx2 activity, as well as by repression of Runx2's antiproliferative effects via cyclin D1 upregulation. (data not shown), we abolished Notch signaling by generating null mice for both presenilin-1 (Psen1) and presenilin-2 (Psen2). Because Psen2-null mice are viable and fertile, we generated double homozygotes for the Psen2-null allele and the Psen1 floxed allele, but heterozygous for the type 1 collagen Cre recombinase transgene (Psen1 f/f Psen2 -/-Col1a1 Cre/+ , or DKO). DKO mice were compared to their Psen1 f/f Psen2 -/-littermates as controls, and efficient deletion of the Psen1 f/f allele (approximately 92%) was confirmed by RT-PCR for presenilin mRNA expression and genomic PCR for DNA recombination in both calvarial osteoblasts and tail DNA, respectively (Supplementary Fig. 2a,b online) . Moreover, we confirmed that this led to decreased NICD processing by western blot analysis ( Supplementary  Fig. 2c ). Histomorphometric analyses of DKO mice showed that 6-month-old, but not 3-month-old, mice were osteoporotic, a decreased tissue bone mass phenotype that is the opposite of the osteosclerotic tissue phenotype in gain-of-Notch-function transgenic mice (Fig. 3a-c) . Bone formation rates, osteoblast surfaces and mineralized surfaces in vertebrae and long bones in the DKO mice were similar to those in control mice ( Supplementary Fig. 3 online) . However, osteoclast numbers, osteoclast surfaces and eroded surfaces were increased in DKO vertebrae and long bones at 6 months of age, but not at 3 months of age (Fig. 3d,e and Supplementary Fig. 3 ). These findings suggest that loss of Psen1 and Psen2, and thus all Notch signaling in osteoblasts, led to osteoporosis through activation of osteoclastogenesis and the subsequent increased bone resorption over bone formation with age-related penetrance. Activated osteoblasts support osteoclast formation and differentiation from osteoclast precursors by expressing M-CSF and RANKL, but they also inhibit this process through osteoprotegerin, which binds to and inactivates RANKL. To further examine the effects of loss of Psen1 and Psen2 in osteoblasts on osteoclastogenesis, we performed osteoblast-osteoclastic precursor (OCP) coculture studies. In this ex vivo assay, P7 DKO calvarial osteoblasts stimulated the formation of more osteoclasts from wild-type, spleen-derived OCPs than did wild-type osteoblasts, suggesting that Psen1 and Psen2 deletions can affect osteoclastogenesis in a non-cell-autonomous fashion (Fig. 4a) . To determine whether this effect was specific for Notch signaling, we tested whether heterologous expression of N1ICD after lentiviral transduction of DKO osteoblasts could suppress osteoclastogenesis in coculture studies ( Fig. 4b and Supplementary Fig. 4a online) . Compared to control vector expressing EGFP, lentiviral transduction of N1ICD into Psen1-Psen2 mutant osteoblasts was able to suppress osteoclastogenesis, suggesting that the DKO phenotype was primarily due to presenilin effects on Notch signaling.
The in vivo relevance of this was confirmed by flow cytometric analysis of markers on bone marrow cells from 3-month-old DKO mice. This showed increased staining of early OCPs in total cells (cFMS + ) and in more differentiated OCPs (CD11b + Gr-1 -/lo ) compared to controls, indicating an expansion of the OCP pool in DKO mice (Fig. 4c) . To determine whether this increase in osteoclast differentiation was due to an imbalance of osteoblastic inductive (RANKL and M-CSF) versus suppressive (osteoprotegerin) signals, we analyzed their mRNA expression in DKO versus control bone at P4. We found comparable expression of RANKL mRNA in DKO and control mice, but expression of osteoprotegerin mRNA was markedly decreased (Fig. 4d) in DKO mice. Similarly, we found decreased osteoprotegerin production in cultured DKO calvarial osteoblasts as compared to wild-type calvarial osteoblasts (Supplementary Fig. 4b ). Hence, under physiological conditions, Notch signaling enabled by Psen1 and Psen2 function in osteoblasts represses osteoclast differentiation by regulating osteoprotegerin expression.
Together, these in vivo gain-of-function and loss-of-function studies lend support for a central role of Notch and presenilin signaling in regulating both osteoclastogenesis and immature osteoblastic proliferation during bone homeostasis (Fig. 5) .
DISCUSSION
Until now, few primary signaling mechanisms regulating osteoblast differentiation and function during bone homeostasis have been identified in vivo by genetic and biochemical studies. Wnt signaling via LRP5/6 coreceptors and canonical b-catenin activity are required for osteoblast lineage commitment and function [17] [18] [19] . Activation of this pathway leads to high bone mass 20, 21 . Activating mutations in transforming growth factor-b in humans is associated with increased bone formation and inhibition of bone resorption 22 . However, and not unexpectedly, apparently discrepant results in vivo have been observed, depending on the timing of the gain versus the loss of transforming growth factor-b function. Similarly, Notch signaling probably has temporal and spatial dependence, as well.
In bone, our data suggest that Notch and presenilin signaling may be important in the physiological regulation of osteoclastogenesis by osteoblasts. Moreover, it raises the question of whether loss of Notch signaling contributes to age-related osteoporosis, as this type of osteoporosis is associated with increased resorption over bone formation 23 , as is seen in our DKO model. We discovered that one function of Notch in committed osteoblasts is to regulate osteoclastogenesis via regulation of osteoprotegerin production. The magnitude of osteoprotegerin dysregulation and the age-related penetrance of the osteoporosis in the loss-of-function mouse phenotype correlate well with epidemiological data in humans, in which age-related osteoporosis has been associated with changes in osteoprotegerin production [24] [25] [26] [27] . Furthermore, the report that heterozygote osteoprotegerin-mutant mice have an age-related osteoporotic phenotype suggests that this mechanism is sufficient for disease pathogenesis 28 . What is unclear is whether osteoprotegerin dysregulation is due to direct regulation by N1ICD or by its target transcription factors, given the still poorly characterized osteoprotegerin genetic regulatory region. Further studies showing chromatin immunoprecipitation analysis of a welldefined functional osteoprotegerin promoter with N1ICD or with its target genes would help to address this issue. Likewise, our studies do not address the potential role of Notch signaling before osteoblastic commitment in the mesenchymal stem cell (Fig. 5) . Here, Runx2 has the central role in osteoblastic commitment. Our data on the NotchRunx2 interaction suggest that early loss of function of Notch would actually lead to increased commitment to the osteoblastic lineage and perhaps depletion of the mesenchymal stem cell compartment. In a pathological disease context, our findings show that activation of Notch signaling in the committed osteoblastic lineage leads to expansion of an immature osteoblast pool. The primary mode of action is transcriptional upregulation of the early osteoblast transcription factor osterix and increase of cyclin D and cyclin E proteins. These data raise the question of the potential contribution of activation of Notch signaling in human diseases related to osteoblastic proliferation, such as in bone pathologies including human osteosarcomas. The substantial upregulation of cyclin D1 in the transgenic mice correlates with the observation in humans that 10% of osteosarcomas show amplification of the chromosomal region encoding cyclin D1(ref. 29) . Although our data suggest that Notch can directly interact with Runx2 to inhibit its binding to target cis elements and its prodifferentiation function, this is probably not the main determinant of the gain-of-function phenotype in mice.
Finally, our data have key therapeutic implications. There are few anabolic bone agents for the treatment of osteoporosis, with most therapies targeted at inhibition of bone resorption. Upregulation of Notch signaling may represent a potential approach for increasing bone formation over bone resorption, as well as for inhibiting osteoclastogenesis. However, it is clear that temporal effects of Notch on other cellular compartments, such as the mesenchymal stem cell pool, would have to be considered; that is, Notch inhibition of Runx2 function could inhibit mesenchymal stem cell commitment to the osteoblastic lineage. In opposing fashion, inhibition of Notch signaling may be a therapeutic option to investigate for the treatment of proliferative disorders of the osteoblast, such as osteosclerotic diseases or bone cancers.
From a mechanistic perspective, the function of Notch signaling in bone constitutes an example of a signaling pathway capable of regulating both osteoblastic and osteoclastic lineages. Gain of Notch function in osteoblasts affects osteoblastic differentiation in a cellautonomous fashion, whereas loss of Notch function in osteoblasts affects osteoclastogenesis in a non-cell-autonomous manner. A remaining question is how Notch-Notch ligand interactions with neighboring cells, such as stromal and osteoclastic cells, may further modify biological function in the respective lineages. For example, ephrin B2 signaling in bone is bidirectional, with consequences for both the cells expressing the ligand and the cells expressing the receptor. In this case, reverse signaling through ephrin B2 ligand expressed by osteoclasts suppresses osteoclast precursors, whereas forward signaling through EphB4 receptor expressed by osteoblasts enhances osteoblast formation 30, 31 . Together, our data point to a dimorphic role for Notch signaling in osteoblast biology; that is, the stimulation of osteoblastic precursors in a pathological context and the inhibition of osteoclastogenesis in the physiological regulation of bone mass and homeostasis.
METHODS
Mice. We cloned Myc-His-tagged N1ICD, which includes amino acids 1760-2556 of Notch (gift of T. Kadesch), under the control of the 2.3-kilobase (kb) osteoblast-specific Col1a1 promoter in a coat-color vector containing the tyrosinase minigene and the woodchuck posttranscriptional regulatory element (WPRE) sequences 32 . We generated transgenic founders by pronuclear injections using standard techniques. We maintained all transgenic lines on a FVB/N background. We identified the transgenic mice at birth by eye pigmentation and confirmed by PCR using primers specific for the WPRE. We crossed previously described Psen1 f/f and Psen2 -/-mice with Col1a1-Cre mice (gift of G. Karsenty) to generate osteoblast-specific Psen1-Psen2 DKO mice. These studies were approved by the Baylor College of Medicine Institutional Animal Care and Use Committee.
Skeletal analyses, histology and bone histomorphometry. We cleared and stained skeletons from 1-month-old mice with Alcian blue for cartilage and Alizarin red for bone as described 33 . We killed the mice and fixed the whole skeleton in 10% neutral-buffered formalin for 18 h. For radiographic analyses, we analyzed the skeletons by contact radiography with a Faxitron X-ray cabinet (Faxitron X-ray). We sectioned paraffin-embedded tissues to a 4-7-mm thickness and stained the section with H&E. We performed toluidine blue, Von Kossa and Goldner's stains on 5-7-mm undecalcified lumbar vertebral plastic sections by using standard protocols. We performed all static and dynamic histomorphometry analyses according to standard protocols using the OsteoMeasure histomorphometry system (Osteometrics). We performed histomorphometric analyses on 4-week-old transgenic mice (n ¼ 3) and 6-month-old knockout mice (n ¼ 5-7).
We analyzed m-computed tomography (mCT) scanning of the trabecular bone of the distal femur by the mCT system (mCT-40, Scanco Medical).
Plasmids. Osterix-luciferase was a gift of M.S. Nanes. For lentivirus vector production, we constructed plasmid pHIV-N1-IRES-eYFP by inserting a FLAG-tagged version of intracellular activated form of Notch1 (N1), just upstream of the 1.4-kb IRES-eYFP cassette (an internal ribosomal entry site fused to enhanced yellow fluorescence protein) of pHIV-IRES-eYFP 34 . For the primary osteoblasts, the lentiviral vectors used were self-inactivating and had the 0.5-kb mouse phosphoglycerate kinase promoter inserted upstream of either N1-IRES-eYFP or IRES-eYFP 35 . We produced vesicular stomatitis virus G protein-pseudotyped vector supernatants as previously described 36 . After 72 h, we harvested cell culture supernatants and clarified them. Typical titers after concentration by ultracentrifugation were in excess of 1 Â 10 8 international units (IU)/ml for the two self-inactivating vectors as assessed on HOS cells by epifluorescence microscopy. Titers of unconcentrated non-SIN vectors were in excess of 1 Â 10 7 IU/ml.
Coculture studies. We cocultured 5 Â 10 3 calvarial osteoblasts from 1-weekold mice (n ¼ 3) with 5 Â 10 4 spleen cells per well in 96-well plates for 7 d in the presence 10 À8 M vitamin D 3 . We then stained the cells for TRAP activity and counted as described previously 37 . For the lentiviral rescue experiment, we cultured 5 Â 10 3 osteoblasts isolated from calvaria of 10-d-old Psen1-Psen2 DKO mice in a 96-well plate for 2 d. We then infected the cells with either 5 ml N1ICD lentivirus or the YFP lentiviral vector supernatant for 24 h in 100 ml a-MEM containing 10% FBS and 8 mg polybrene/ml. We then cocultured the infected cells with 5 Â 10 4 spleen cells from 10-d-old WT mice for 7 d in the presence of 10 À8 M vitamin D 3 .
Fluorescence-activated cell sorting and cell sorting analyses. After lysis of erythrocytes with ammonium chloride solution, we incubated 2 Â 10 6 cells from bone marrow or spleen for 5 min with antibody to murine CD16/32 to block Fc receptor-mediated antibody binding, and then followed with triple staining with allophycocyanin-conjugated antibody to mouse CD11b, FITCconjugated antibody to Gr-1 and phycoerythrin-conjugated antibody to c-Fms for 30 min. We then subjected the cells to FACS to analyze the CD11b + Gr-1 -/lo cells that contain osteoclast precursors and c-Fms + cells in both the total gated and the CD11b + Gr-1 -/lo populations.
Bromodeoxyuridine incorporation. We isolated osteoblasts from calvaria of P6 transgenic mice and wild-type littermates (n ¼ 5 per group) as previously described 33 . We replated cells 48 h after the initial culture and expanded them for an additional day. We treated cells with BrdU labeling reagent (Zymed) according to the manufacturer's instructions for 6 h, washed them with PBS and fixed them with 70% ethanol for 25 min at 4 1C. Three to five areas for each genotype (n ¼ 3 slides) were counted by two independent observers blinded to genotype. We scored BrdU-positive cells over total cells visually and with Automeasure software (Zeiss Axiovision).
